■ A team of international researchers set out to determine the efficacy and safety of the Xen gel stent (Allergan) in both standalone and combination ab-interno procedures after 3 years. Mean IOP and medications in 163 eyes decreased from 20.7 mmHg and 2.5 medications at baseline to 13.9 mmHg and 1.1 medications at 3 years. Mean changes from baseline in IOP (-5.6, -6.2, and -6.6 mmHg) and medications (-1.8, -1.6, and -1.4) were statistically significant at 1, 2, and 3 years after implantation, respectively. Results appeared comparable when implantation was performed with (n=76) or without (n=98) phacoemulsification. Fifteen eyes had intraoperative complications, 31 experienced 46 postoperative adverse events of special interest, and 26 required secondary surgical interventions. The study was reported in Acta Ophthalmologica.